title: The determinants of pricing in pharmaceuticals: are US prices really so high?
abstract: This paper studies price determination in pharmaceutical markets using data for 25 countries, 6 years, and a comprehensive list of products from the MIDAS IMS database. A key finding is that the USA has prices that are not significantly higher than those of countries with similar income levels, especially those that are 'lightly regulated'. More importantly, price differences to the US levels increase for 'branded', world top selling, or innovative products, and decrease, regardless of the level of regulation for mature or widely diffused molecules. Because prices for top selling molecules may be easier to perceive and recollect and more important for companies, they may bias the public discussion about international price differences.
authors.affiliation: Universidad Carlos III de Madrid, Economics, Spain.
authors.forename: Antonio
authors.initials: A
authors.lastname: Cabrales
authors.forename: Sergi
authors.initials: S
authors.lastname: Jiménez-Martín
mesh_terms: D016527:Drug Costs / Q000706:statistics & numerical data; D006801:Humans; D017059:Models, Econometric; D004364:Pharmaceutical Preparations / Q000191:economics; D014481:United States
chemical_list: D004364:Pharmaceutical Preparations
keywords: I10; I18; L18; L65; pharmaceutical prices; regulation